BTAI.US BioXcel Therapeutics Inc

Biotechnology USA Stocks
0.0739 USD
Close of Sep 13, 2026
0.0190 2.33
Market cap
USD 2.31M
P/E
-
P/B
27.50x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BTAI.US undervalued?

Graham number

The Graham number of BioXcel Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioXcel Therapeutics Inc fundamental analysis

No fundamental analysis for BioXcel Therapeutics Inc yet.

BioXcel Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational…

Full company profile